Tci GeneROCO:6879 65 Gross Margin % is 58.33% as of Dec. 2025, which is 2% above its 10-year median of 57.39. GuruFocus rates ROCO:6879 with a GF Score™ of 65/100 and a GF Value™ of NT$49.23 (Modestly Undervalued). The stock has 7 warning signs investors should review. Among 732 Biotechnology companies, Tci Gene ranks worse than 55.19% on this metric.
Gross Margin % is calculated as gross profit divided by its revenue. Tci Gene's Gross Profit for the
six
months ended in Dec. 2025 was NT$76.9 Mil. Tci Gene's Revenue for the
six
months ended in Dec. 2025 was NT$131.9 Mil. Therefore, Tci Gene's Gross Margin % for the quarter that ended in Dec. 2025 was 58.33%.
Warning Sign:
Tci Gene Inc gross margin has been in long-term decline. The average rate of decline per year is -1.2%.
The historical rank and industry rank for Tci Gene's Gross Margin % or its related term are showing as below:
ROCO:6879'
s Gross Margin % Range Over the Past 10 Years
Min: 52.3 Med: 57.39 Max: 70.21
Current: 55.77
During the past 7 years, the highestGross Margin % of Tci Gene was 70.21%. The lowest was 52.30%. And the median was 57.39%.
ROCO:6879's Gross Margin % is ranked worse than 55.19% of 732
companies
in the Biotechnology industry
Industry Median: 60.91
vs ROCO:6879: 55.77
Tci Gene had a gross margin of 58.33% for the quarter that ended in Dec. 2025 => Durable competitive advantage
The 5-Year average Growth Rate of Gross Margin for Tci Gene was -1.20% per year.
Tci Gene (ROCO:6879) Gross Margin % Explanation
Warren Buffett believes that firms with excellent long term economics tend to have consistently higher margins.
Durable competitive advantage creates a high Gross Margin % because of the freedom to price in excess of cost. Companies can be categorized by their Gross Margin %
1. Greater than 40% = Durable competitive advantage
2. Less than 40% = Competition eroding margins
3. Less than 20% = no sustainable competitive advantage
Consistency of Gross Margin is key
Tci Gene had a gross margin of 58.33% for the quarter that ended in Dec. 2025 => Durable competitive advantage
Be Aware
If a company loses its competitive advantages, usually its gross margin declines well before its sales declines. Watching Gross Margin % and Operating Margin % closely helps avoid value trap situations.
Tci Gene Gross Margin % Related Terms
Tci Gene Gross Margin % Historical Data
* Premium members only.
The historical data trend for Tci Gene's Gross Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
ROCO:6879 vs VRTX, REGN, ALNY: Gross Margin % Comparison
For the Biotechnology subindustry, Tci Gene's Gross Margin %, along with its competitors' market caps and Gross Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Tci Gene Gross Margin % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Tci Gene's Gross Margin % distribution charts can be found below:
* The bar in red indicates where Tci Gene's Gross Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
A positive Gross Profit is only the first step for a company to make a net profit. The gross profit needs to be big enough to also cover related labor, equipment, rental, marketing/advertising, research and development and a lot of other costs in selling the products.
Tci Gene (ROCO:6879) has a Gross Margin % of 58.33% as of Dec. 2025. Gross margin is the ratio of total gross profit to net sales. View historical data on Tci Gene and its competitors. This is near median its historical median of 57.39. Over the past decade, Tci Gene's Gross Margin % has ranged from 52.30 to 70.21. According to the industry distribution chart, Tci Gene ranks #404 out of 732 companies in the Biotechnology industry, placing it in the top 55.2%.
Is Tci Gene's Gross Margin % too high?
Tci Gene's current Gross Margin % of 58.33% is near median its 10-year median of 57.39. Over the past 10 years, this metric has ranged from a low of 52.30 to a high of 70.21. The Biotechnology industry median Gross Margin % is 60.91. Tci Gene's value of 58.33% is 4.2% below this industry median. Based on the distribution chart, Tci Gene ranks #404 out of 732 companies in the Biotechnology industry, which is below the industry midpoint. Overall, Tci Gene has a GF Score™ of 65/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Tci Gene's Gross Margin % compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Tci Gene ranks #404 out of 732 companies for Gross Margin %. This places Tci Gene in the lower half of its industry. The industry median Gross Margin % is 60.91. Tci Gene's value of 58.33% is 4.2% below this benchmark. Historically, Tci Gene's own Gross Margin % has ranged from 52.30 to 70.21 over the past decade. While the company's 10-year median is 57.39 vs. the industry median of 60.91, Tci Gene has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Gross Margin % for a Biotechnology company?
The median Gross Margin % among Biotechnology companies is 60.91, based on 732 companies in the industry. Companies in the top quartile (top 25%) have a Gross Margin % significantly above this median, while those in the bottom quartile fall well below. However, Gross Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Tci Gene's current Gross Margin % of 58.33% is 4.2% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Gross Margin % mean?
A high Gross Margin % can signal that a stock is expensive relative to its fundamentals. Gross margin is the ratio of total gross profit to net sales. View historical data on Tci Gene and its competitors. For the Biotechnology industry, the median Gross Margin % is 60.91 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Tci Gene's current Gross Margin % is 58.33%, which is near median its own 10-year median of 57.39. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Tci Gene stock overvalued right now?
Based on GuruFocus' analysis, Tci Gene (ROCO:6879) is currently considered Modestly Undervalued. The stock's GF Value™ is NT$49.23, compared to a current price of NT$37.00 — trading 24.8% below its estimated fair value. The current Gross Margin % is 58.33%, which is near median its 10-year median of 57.39 and 4.2% below the Biotechnology industry median of 60.91. Tci Gene's overall GF Score™ is 65/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Gross Margin % calculated?
Gross Margin % is calculated from a company's financial statements. For Tci Gene (ROCO:6879), the current Gross Margin % is 58.33% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Tci Gene (ROCO:6879) Overvalued in 2026?
Based on GuruFocus' analysis, Tci Gene stock appears to be undervalued.
The current stock price of NT$37.00 is trading 24.8% below its estimated GF Value™ of NT$49.23.
GuruFocus considers Tci Gene to be Modestly Undervalued.
Key valuation signals for ROCO:6879:
Gross Margin %: 58.33% (near median its 10-year median of 57.39)
GF Value™: NT$49.23 vs. price of NT$37.00 (24.8% below fair value)
Industry Position: 4.2% below the Biotechnology median (#404 of 732)
No single metric tells the full story. See the ROCO:6879 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Tci Gene Inc provides precision preventive medicines in Taiwan. It is the first to introduce the concept of precision preventive medicine with Predict prediction, Prevent prevention, and Personal Treatment personalized health management measures.
65GF Score
Get the complete analysis for ROCO:6879
Gross Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ROCO:6879 has been successfully added to your 
